|
1
|
Socinski MA, Crowell R, Hensing TE, et al:
Treatment of non-small cell lung cancer, stage IV: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132:S277–S289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nayak L, Lee EQ and Wen PY: Epidemiology
of brain metastases. Curr Oncol Rep. 14:48–54. 2012. View Article : Google Scholar
|
|
3
|
Shi AA, Digumarthy SR, Temel JS, et al:
Does initial staging or tumor histology better identify
asymptomatic brain metastases in patients with non-small cell lung
cancer? J Thorac Oncol. 1:205–210. 2006.PubMed/NCBI
|
|
4
|
Gaspar L, Scott C, Rotman M, Asbell S,
Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive
partitioning analysis (RPA) of prognostic factors in three
Radiation Therapy Oncology Group (RTOG) brain metastases trials.
Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Penel N, Brichet A, Prevost B, et al:
Prognostic factors of synchronous brain metastases from lung
cancer. Lung Cancer. 33:143–154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ampil F, Caldito G, Milligan S, et al: The
elderly with synchronous non-small cell lung cancer and solitary
brain metastasis: does palliative thoracic radiotherapy have a
useful role? Lung Cancer. 57:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanchez de Cos J, Sojo Gonzalez MA,
Montero MV, et al: Non-small cell lung cancer and silent brain
metastasis. Survival and prognostic factors. Lung Cancer.
63:140–145. 2009.PubMed/NCBI
|
|
8
|
Tsao MN, Lloyd N, Wong RK, et al: Whole
brain radiotherapy for the treatment of newly diagnosed multiple
brain metastases. Cochrane Database Syst Rev. 4:CD0038692012.
|
|
9
|
DeAngelis LM, Mandell LR, Thaler HT, et
al: The role of postoperative radiotherapy after resection of
single brain metastases. Neurosurgery. 24:798–805. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shibamoto Y, Baba F, Oda K, et al:
Incidence of brain atrophy and decline in mini-mental state
examination score after whole-brain radiotherapy in patients with
brain metastases: a prospective study. Int J Radiat Oncol Biol
Phys. 72:1168–1173. 2008. View Article : Google Scholar
|
|
11
|
Meyers CA, Smith JA, Bezjak A, et al:
Neurocognitive function and progression in patients with brain
metastases treated with whole-brain radiation and motexafin
gadolinium: results of a randomized phase III trial. J Clin Oncol.
22:157–165. 2004. View Article : Google Scholar
|
|
12
|
Li J, Bentzen SM, Renschler M and Mehta
MP: Regression after whole-brain radiation therapy for brain
metastases correlates with survival and improved neurocognitive
function. J Clin Oncol. 25:1260–1266. 2007. View Article : Google Scholar
|
|
13
|
Tallet AV, Azria D, Barlesi F, et al:
Neurocognitive function impairment after whole brain radiotherapy
for brain metastases: actual assessment. Radiat Oncol. 7:772012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patchell RA, Tibbs PA, Walsh JW, et al: A
randomized trial of surgery in the treatment of single metastases
to the brain. N Engl J Med. 322:494–500. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vecht CJ, Haaxma-Reiche H, Noordijk EM, et
al: Treatment of single brain metastasis: radiotherapy alone or
combined with neurosurgery? Ann Neurol. 33:583–590. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mintz AH, Kestle J, Rathbone MP, et al: A
randomized trial to assess the efficacy of surgery in addition to
radiotherapy in patients with a single cerebral metastasis. Cancer.
78:1470–1476. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wronski M and Lederman G: A randomized
trial to assess the efficacy of surgery in addition to radiotherapy
in patients with a single cerebral metastasis. Cancer.
80:1002–1004. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bindal RK, Sawaya R, Leavens ME and Lee
JJ: Surgical treatment of multiple brain metastases. J Neurosurg.
79:210–216. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Andrews DW, Scott CB, Sperduto PW, et al:
Whole brain radiation therapy with or without stereotactic
radiosurgery boost for patients with one to three brain metastases:
phase III results of the RTOG 9508 randomised trial. Lancet.
363:1665–1672. 2004. View Article : Google Scholar
|
|
20
|
Aoyama H, Shirato H, Tago M, et al:
Stereotactic radiosurgery plus whole-brain radiation therapy vs.
stereotactic radiosurgery alone for treatment of brain metastases:
a randomized controlled trial. JAMA. 295:2483–2491. 2006.
View Article : Google Scholar
|
|
21
|
Walbert T and Gilbert MR: The role of
chemotherapy in the treatment of patients with brain metastases
from solid tumors. Int J Clin Oncol. 14:299–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deeken JF and Loscher W: The blood-brain
barrier and cancer: transporters, treatment, and Trojan horses.
Clin Cancer Res. 13:1663–1674. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mehta MP, Paleologos NA, Mikkelsen T, et
al: The role of chemotherapy in the management of newly diagnosed
brain metastases: a systematic review and evidence-based clinical
practice guideline. J Neurooncol. 96:71–83. 2010. View Article : Google Scholar
|
|
24
|
Robinet G, Thomas P, Breton JL, et al:
Results of a phase III study of early versus delayed whole brain
radiotherapy with concurrent cisplatin and vinorelbine combination
in inoperable brain meta- stasis of non-small-cell lung cancer:
Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann
Oncol. 12:59–67. 2001.
|
|
25
|
Lee DH, Han JY, Kim HT, et al: Primary
chemotherapy for newly diagnosed nonsmall cell lung cancer patients
with synchronous brain metastases compared with whole-brain
radiotherapy administered first: result of a randomized pilot
study. Cancer. 113:143–149. 2008. View Article : Google Scholar
|
|
26
|
Moscetti L, Nelli F, Felici A, et al:
Up-front chemotherapy and radiation treatment in newly diagnosed
nonsmall cell lung cancer with brain metastases: survey by Outcome
Research Network for Evaluation of Treatment Results in Oncology.
Cancer. 109:274–281. 2007. View Article : Google Scholar
|
|
27
|
Kim KH, Lee J, Lee JI, et al: Can upfront
systemic chemotherapy replace stereotactic radiosurgery or whole
brain radiotherapy in the treatment of non-small cell lung cancer
patients with asymptomatic brain metastases? Lung Cancer.
68:258–263. 2010. View Article : Google Scholar
|
|
28
|
Peters S, Adjei AA, Gridelli C, et al:
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical
Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 23(Suppl 7): vii56–vii64. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Barlesi F, Gervais R, Lena H, et al:
Pemetrexed and cisplatin as first-line chemotherapy for advanced
non-small-cell lung cancer (NSCLC) with asymptomatic inoperable
brain metastases: a multicenter phase II trial (GFPC 07-01). Ann
Oncol. 22:2466–2470. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bailon O, Chouahnia K, Augier A, et al:
Upfront association of carboplatin plus pemetrexed in patients with
brain metastases of lung adenocarcinoma. Neuro Oncol. 14:491–495.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Reck M, von Pawel J, Zatloukal P, et al:
Overall survival with cisplatin-gemcitabine and bevacizumab or
placebo as first-line therapy for nonsquamous non-small-cell lung
cancer: results from a randomised phase III trial (AVAiL). Ann
Oncol. 21:1804–1809. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Soria JC, Mauguen A, Reck M, et al:
Systematic review and meta-analysis of randomised, phase II/III
trials adding bevacizumab to platinum-based chemotherapy as
first-line treatment in patients with advanced non-small-cell lung
cancer. Ann Oncol. 24:20–30. 2013. View Article : Google Scholar
|
|
34
|
Azzoli CG, Baker S Jr and Temin S;
American Society of Clinical Oncology. American Society of Clinical
Oncology Clinical Practice Guideline update on chemotherapy for
stage IV non-small-cell lung cancer. J Clin Oncol. 27:6251–6266.
2009. View Article : Google Scholar
|
|
35
|
Gordon MS, Margolin K, Talpaz M, et al:
Phase I safety and pharmacokinetic study of recombinant human
anti-vascular endothelial growth factor in patients with advanced
cancer. J Clin Oncol. 19:843–850. 2001.PubMed/NCBI
|
|
36
|
Srivastava G, Rana V, Wallace S, et al:
Risk of intracranial hemorrhage and cerebrovascular accidents in
non-small cell lung cancer brain metastasis patients. J Thorac
Oncol. 4:333–337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khasraw M, Holodny A, Goldlust SA and
DeAngelis LM: Intracranial hemorrhage in patients with cancer
treated with bevacizumab: the Memorial Sloan-Kettering experience.
Ann Oncol. 23:458–463. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carden CP, Larkin JM and Rosenthal MA:
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro Oncol. 10:624–630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Besse B, Lasserre SF, Compton P, et al:
Bevacizumab safety in patients with central nervous system
metastases. Clin Cancer Res. 16:269–278. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Socinski MA, Langer CJ, Huang JE, et al:
Safety of bevacizumab in patients with non-small-cell lung cancer
and brain metastases. J Clin Oncol. 27:5255–5261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Besse B, Le Moulec S, Senellart H, et al:
Phase II study of bevacizumab in combination with first-line
chemotherapy or second-line erlotinib in non-squamous NSCLC
patients with asymptomatic untreated brain metastases (ML21823).
Ann Oncol. 23:ix4262012.
|
|
42
|
De Braganca KC, Janjigian YY, Azzoli CG,
et al: Efficacy and safety of bevacizumab in active brain
metastases from non-small cell lung cancer. J Neurooncol.
100:443–447. 2010.PubMed/NCBI
|
|
43
|
Yamamoto D, Iwase S, Tsubota Y, et al:
Bevacizumab in the treatment of five patients with breast cancer
and brain metastases: Japan Breast Cancer Research Network-07
trial. Onco Targets Ther. 5:185–189. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tsao MN, Lloyd NS and Wong RK; Supportive
Care Guidelines Group of Cancer Care Ontario’s Program in
Evidence-based Care. Clinical practice guideline on the optimal
radiotherapeutic management of brain metastases. BMC Cancer.
5:342005. View Article : Google Scholar : PubMed/NCBI
|
